^
Association details:
Biomarker:EGFR E746_A750del
Cancer:Non Small Cell Lung Cancer
Drug:gefitinib (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Excerpt:
Characteristics of patients sensitive to gefitinib (G) and erlotinib (E)....Four of the exon 19 deletion mutations were the same as the previously described del E746-A750….Deletion mutations in exon 19 of EGFR from NSCLCs sensitive to TKIs, gefitinib (G) or erlotinib (E).
DOI:
10.1073/pnas.0405220101
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants

Excerpt:
In different EGFR variant-expressing 32D cells, only cells harboring L858R, E746-A750 deletion, and G719S mutants were clearly more sensitive to gefitinib than wild-type EGFR-expressing cells. 
DOI:
10.1038/sj.onc.1209159